Clinicopathologic conference: Bloodstream infection in an allogeneic hamatopoietic cell transplant: Thinking beyond the usual.
Détails
Télécharger: 38695847.pdf (850.59 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_6497609B679D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Clinicopathologic conference: Bloodstream infection in an allogeneic hamatopoietic cell transplant: Thinking beyond the usual.
Périodique
Transplant infectious disease
ISSN
1399-3062 (Electronic)
ISSN-L
1398-2273
Statut éditorial
Publié
Date de publication
08/2024
Peer-reviewed
Oui
Volume
26
Numéro
4
Pages
e14273
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article ; Clinical Conference
Publication Status: ppublish
Publication Status: ppublish
Résumé
This case involves a 53-year-old female with concurrent acute myeloid leukemia (AML) and multiple myeloma. She underwent cytarabine and daunorubicin (7+3) induction chemotherapy followed by cytarabine (HiDAC) consolidation, with an early AML relapse requiring azacitidine and venetoclax therapy. She achieved complete remission and incomplete count recovery. Following fludarabine, melphalan, and thymoglobulin induction chemotherapy, she underwent an allogeneic stem cell transplant with failure to engraft, requiring autologous stem cell rescue, buffy coat, and granulocyte transfusions, eventually presenting with a diffuse skin rash consistent with Steven-Johnson syndrome and toxic epidermal necrolysis, persistent neutropenic fevers and positive blood cultures.
Mots-clé
Humans, Middle Aged, Female, Leukemia, Myeloid, Acute/therapy, Leukemia, Myeloid, Acute/complications, Multiple Myeloma/therapy, Hematopoietic Stem Cell Transplantation/adverse effects, Transplantation, Homologous/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Cytarabine/therapeutic use, Cytarabine/administration & dosage, Induction Chemotherapy, bloodstream infection, hematopoietic stem cell transplant, immunocompromised
Pubmed
Web of science
Open Access
Oui
Création de la notice
06/05/2024 11:08
Dernière modification de la notice
13/08/2024 6:54